Table 1 Patients’ characteristics and the comparison for characteristics and outcomes in PTCY and non-PTCY groups

Age, years

5.8 (1.1,13.5)

6.04 (SD = 3.13)

6.15 (SD = 3.47)

0.913

Sex, n

male

37

23

14

0.557

female

15

8

7

Weight, kg

17.6 (9.0, 42.4)

19.35 (SD = 7.47)

18.60 (SD = 6.35)

0.707

Primary diagnosis, n

AML

27

19

8

0.259

ALL

23

11

12

others

2

1

1

Remission status, n

CR1

47

27

20

0.329

CR2

5

4

1

HLA matching, n

7/10

4

3

1

0.704

8/10

22

14

8

9/10

17

10

7

10/10

9

4

5

HLA matching 2, n

7/10 or 8/10

26

17

9

0.329

9/10 or 10/10

26

14

12

TNC, 10⁷/kg (range)

6.15 (3.3, 15.3)

6.78 (5.5, 8.06)

6.31 (3.29, 11.15)

0.801

CD34⁺, 10⁵/kg (range)

2.61 (0.72, 11.6)

3.25 (1.26, 10.7)

1.97 (0.72, 11.6)

0.003

Follow-up, months (range)

21.6 (1.8, 38.2)

14.4 (1.8, 30.0)

34.3 (2.2, 38.1)

 < 0.001

Neutrophil engraftment, days (range)

14 (11, 22)

15.8 (14.6, 16.9)

14.5 (11,19)

0.160

PLT engraftment, days (range)

32 (12, 61)

31.9 (27.8, 35.9)

34.5 (13, 52)

0.233

Graft failure, n (%)

2 (4)

1 (3)

1 (5)

0.777

PES, n (%)

45 (87)

25 (81)

20 (95)

0.130

Corticosteroid responding PES, n (%)

38 (73)

17 (71)

19 (95)

0.054

Acute GvHD, n (%)

42 (81)

24 (77)

18 (86)

0.456

Grade 3 and 4 Acute GvHD, n (%)

20 (38)

13 (42)

7 (33)

0.532

HC, n (%)

14 (27)

7 (23)

7 (33)

0.431

Chronic GvHD, n (%)

24 (46)

13 (42)

11 (52)

0.458

EBV activity, n (%)

1(2)

0 (0)

1 (5)

0.404

CMV activity, n (%)

6 (12)

5 (16)

1 (5)

0.211

pneumonia, n (%)

17 (33)

10 (32)

7 (33)

0.584

Fungal infection, n (%)

8 (15)

7 (23)

1 (5)

0.081

Sepsis or bacteremia, n (%)

11 (21)

10 (32)

1 (5)

0.017

TRM, n (%)

4 (8)

3 (10)

1 (5)

0.514

Relapse, n (%)

7 (13)

6 (19)

1 (5)

0.130

Event-free survival, n (%)

41 (79)

22 (71)

19 (91)

0.091